F S&P 500
5,106.25 +14.75 (+0.29%) F Dow Jones
38,615.00 +233.00 (+0.61%) F Nasdaq
17,762.25 +112.50 (+0.64%) E-mini Russell 2000 Index Futur
2,023.00 -4.20 (-0.21%) Petróleo
79.12 +0.17 (+0.22%) Oro
2,310.60 +1.00 (+0.04%)
Aprea Therapeutics, Inc. (APRE)
Fuera de horario:
Aprea Therapeutics, Inc.
3805 Old Easton Road
Doylestown, PA 18902
United States
617 463 9385
https://www.aprea.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 7
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Oren Gilad Ph.D. | Co-Founder, CEO, President & Director | 796.95k | N/D | 1968 |
| Dr. Dansu Li Ph.D. | Head of Technology | N/D | N/D | N/D |
| Dr. Lars B. Abrahmsen Ph.D. | Senior VP & Chief Scientific Officer | N/D | N/D | 1957 |
| Mr. Brian Wiley | Senior Vice President of Corporate Development & Strategy | N/D | N/D | 1968 |
| Dr. Michel Afargan Ph.D. | Head of Pharmacology Development | N/D | N/D | N/D |
| Mr. Ze'ev Weiss B.Sc., C.P.A. | Chief Business Advisor | N/D | N/D | 1962 |
| Ms. Andrea Epstein | Controller | N/D | N/D | N/D |
Descripción
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Gestión corporativa
La calificación ISS Governance QuickScore de Aprea Therapeutics, Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 3; Junta: 7; Derechos del accionista: 8; Compensación: 9.
